The 4 Wall Street analysts covering Covista, Inc. hold a median 12-month price target of $160 — +23.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 13 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Covista, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (92): Analysts have, on balance, been raising their forecasts.
Volatility (34): The share price moves around a lot.
Size (24): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CVSA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +23.6% from it.
Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Oct 2026 | BMO Capital | Maintains | Outperform | $148 → $145 |
| 3 Sept 2026 | Truist Securities | Downgrade | Hold | — |
| 3 Sept 2026 | Truist Securities | Downgrade | Hold | $140 |
| 8 June 2026 | Barrington Research | Maintains | Outperform | — |
| 8 June 2026 | Barrington Research | Maintains | Outperform | $170 |
| 11 May 2026 | Truist Securities | Maintains | Buy | — |
| 17 Apr 2026 | Barrington Research | Maintains | Outperform | — |
| 24 Mar 2026 | Truist Securities | Initiates | Buy | — |
| 2 Mar 2026 | Barrington Research | Maintains | Outperform | — |
| 29 Jan 2026 | Barrington Research | Maintains | Outperform | — |
| 31 Oct 2025 | Barrington Research | Maintains | Outperform | — |
| 15 Oct 2025 | Barrington Research | Maintains | Outperform | — |
| 23 Sept 2025 | Barrington Research | Maintains | Outperform | — |
| 8 Aug 2025 | Barrington Research | Maintains | Outperform | $140 → $150 |
| 30 July 2025 | Barrington Research | Maintains | Outperform | $140 |
| 12 May 2025 | BMO Capital | Maintains | Outperform | $115 → $132 |
| 9 May 2025 | Barrington Research | Maintains | Outperform | $120 → $140 |
| 23 Apr 2025 | Jefferies | Initiates | Buy | $135 |
| 15 Apr 2025 | Barrington Research | Maintains | Outperform | $120 |
| 3 Feb 2025 | BMO Capital | Maintains | Outperform | $108 → $115 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CVSA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Covista, Inc. returned −13.5% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 42% of US stocks
Cheaper than 49% of US stocks
Cheaper than 31% of US stocks
Cheaper than 33% of US stocks
Higher than 51% of US stocks
Higher than 67% of US stocks
Higher than 70% of US stocks
Higher than 78% of US stocks
Higher than 75% of US stocks
Higher than 79% of US stocks
Higher than 89% of US stocks
Higher than 64% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Covista, Inc. has a market value of $4.4B and an enterprise value of $4.9B.
Revenue in the twelve months to 30 June 2026: $2.0B. The latest quarter grew 9.7% year on year.
Net income over the same four quarters: $251.6M, a 12.9% net margin.
Diluted earnings per share, trailing twelve months: $7.04.
Free cash flow in the twelve months to 30 June 2026: $392.7M, after $77.7M of capital spending.
Covista, Inc. spent $239.9M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 17.2×; forward P/E: 12.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.28%, paying out 0% of earnings.
Covista, Inc. employs 4,736 people — $413K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Covista, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research explains how its Style Scores help investors identify stocks rated highly for a particular investing style, presenting Covista as a long-term value stock.
Why it matters — CVSA watchers may note the article’s value-investing framing and the role of Zacks Style Scores in its assessment.
Covista said an analysis of Ross University School of Medicine and American University of the Caribbean School of Medicine found that students matched or exceeded U.S. MD peers on first-time USMLE Step 1 pass rates across MCAT ranges. The company said MCAT scores alone do not determine medical-school success and highlighted academic support, student services and outcomes-focused curricula.
Why it matters — The reported pass-rate comparison and emphasis on student support offer CVSA watchers information about academic outcomes at two of its institutions.
Walden University, a Covista (NYSE: CVSA) institution, has been named a DAISY Extraordinary Educational Partner by The DAISY Foundation. The partnership offers DAISY Honorees—nurses recognized for extraordinary, compassionate care—an affordable path to continue their educational and professional growth.
Why it matters — This recognition highlights Walden University's expanded role in nursing education and could strengthen the institution's reputation and appeal for a Covista watcher.
Covista announced it will release its first quarter fiscal year 2027 results on Thursday, October 29, 2026, after market close, followed by a conference call at 4:00 p.m. CT the same day to discuss the results. Dial-in details for U.S. and international participants were provided.
Why it matters — CVSA watchers will want to know the date and logistics for the company's upcoming quarterly earnings release and conference call.
Zacks Investment Research highlights Covista (CVSA) as a strong growth stock, noting that investors can use the Zacks Style Scores to identify top-rated stocks based on investing style.
Why it matters — CVSA watchers would care because the article frames the company favorably as a top growth pick according to Zacks' screening methodology.
The 4 Wall Street analysts covering Covista, Inc. have a median 12-month price target of $160, with estimates ranging from $140 to $175. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Covista, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Covista, Inc. 78 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Oct 2026, Covista, Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (92 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +23.6% from the last close, and Ticker Nerd's factor model ranks Covista, Inc. 78 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Covista, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $140 to $175 over the next 12 months.
Covista, Inc. returned -13.5% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Covista Inc. is a healthcare education company that provides post-secondary training through a portfolio of accredited institutions in the United States and select Caribbean markets.
The most recent item we track (Zacks Investment Research, 14 Oct 2026): "Why Covista (CVSA) is a Top Value Stock for the Long-Term". Zacks Investment Research explains how its Style Scores help investors identify stocks rated highly for a particular investing style, presenting Covista as a long-term value stock.
Covista Inc. is a healthcare education company that provides post-secondary training through a portfolio of accredited institutions in the United States and select Caribbean markets. Its current operations center on preparing students for careers in nursing, medicine, veterinary medicine, and other health-related professions through degree programs, online learning, and campus-based instruction. Covista’s business is organized around Chamberlain, Walden, and Medical and Veterinary segments, each serving different areas of professional education and workforce development. The company supports a broad student population with programs designed for flexible access, academic progression, and clinical preparation, making it an important provider in the healthcare education market. Based in Chicago, Illinois, Covista focuses on serving learners seeking specialized credentials for roles across the healthcare system.
CEO Mr. Stephen W. Beard J.D. · 4,736 employees · United States · https://www.covista.com
